摘要
目的 探讨重组人干扰素α-2b喷雾剂(Recombinant human interferon alpha 2b, rhIFNα-2b)治疗儿童上呼吸道感染疾病的有效性和安全性,为临床合理规范使用rhIFNα-2b喷雾剂提供参考依据。方法 选取我院儿科2020年12月~2021年4月就诊的住院急性上呼吸道感染患儿294例,按治疗方案不同分为对照组和试验组,各147例。两组均采取常规对症治疗,体温<38.5℃时应用物理降温,当体温≥38.5℃采用退热药物缓解。试验组在常规对症处理的基础上应用rhIFNα-2b喷雾剂治疗。观察对比两组患儿的临床疗效、体温恢复正常、咽部疼痛缓解、鼻塞流涕缓解和咳嗽缓解时间及药品不良反应发生情况。结果 两组基线资料平衡,具有可比性。经过治疗,试验组有效率为94%,明显高于对照组61%,差异有统计学意义(P<0.01)。试验组体温恢复正常时间为(1.54±0.72)d,咽部疼痛缓解时间(1.92±0.75)d,鼻塞流涕缓解时间(2.15±0.84)d,咳嗽缓解时间(2.65±0.32)d,均明显优于对照组(P<0.01)。结论 rhIFNα-2b喷雾剂在治疗儿童上呼吸道感染疾病方面见效快,治疗效果优良,有助于降低患儿体温,缓解不适症状,有效治疗上呼吸道感染疾病,患儿对其排斥性小,用药方便且安全,值得儿科临床推广。
OBJECTIVE To investigate the biosafety as well as therapeutic potential of recombinant human interferon alpha 2 b(rhIFNα-2 b) spray for children upper respiratory tract infection, and to provide clinical referral for sequential rational drug usage evaluation.METHODS From December 2020 to April 2021,294 children with acute upper respiratory tract infection were enrolled and divided into experimental group(n=147) and control group(n=147) according to the different treatment regimes.The control group received routine symptomatic treatment(body temperature ≥38.5 ℃ was given antipyretic drug treatment, while body temperature <38.5 ℃ was given physical cooling).The experimental group was given rhIFN α-2 b spray plus routine symptomatic treatment.The clinical efficacy, thebody temperature relief time, symptoms fade time(the disappearance time of pharyngeal pain, nasal congestion, nasal discharge and cough),and adverse reactions of 2 groups were observed.RESULTS Baseline characteristics were balanced and comparable.After treatment, the effective rate of the experimental group was 94%,which was significantly higher than that of control group(61%)(P<0.01).In experimental group, thebody temperature relief time [(1.54±0.72) days],pharyngeal pain relief time [(1.92±0.75) days],nasal congestion and nasal discharge relief time [(2.15±0.84) days],and cough relief time [(2.65±0.32) days]were significantly shorter than those in control group(P<0.01).CONCLUSION rhIFN α-2 b spray exhibited significant therapeutic efficiency in remitting pediatric upper respiratory tract infection in regarding to the rapid relief of fever and symptoms of upper respiratory tract.The satisfied compliance and feasible administration routine may further facilitate its application for pediatric usages.
作者
林明琼
林剑虹
LIN Ming-qiong;LIN Jian-hong(Department of Pharmacy,The Third Hospital of Xiamen,Xiamen 361100,China)
出处
《海峡药学》
2022年第11期138-141,共4页
Strait Pharmaceutical Journal
关键词
儿童
上呼吸道感染
重组人干扰素Α-2B喷雾剂
Children
Upper respiratory tract infection
Recombinant human interferonα-2b spray
